These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment of kala azar. Ozsoylu S Lancet; 1996 Jun; 347(9016):1701. PubMed ID: 8642997 [No Abstract] [Full Text] [Related]
3. Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B. Mishra M J Assoc Physicians India; 1995 Apr; 43(4):306. PubMed ID: 8713286 [No Abstract] [Full Text] [Related]
4. Amphotericin B in visceral leishmaniasis. Jha BB Indian Pediatr; 1996 Nov; 33(11):971. PubMed ID: 9141838 [No Abstract] [Full Text] [Related]
5. [Transitory acute kidney insufficiency and insulin-dependent after treatment of kala-azar with pentamidine and N-methylglucamine antimony]. Morin D; Dumas ML; Valette H; Dumas R Arch Fr Pediatr; 1991 May; 48(5):349-51. PubMed ID: 1859238 [TBL] [Abstract][Full Text] [Related]
6. Challenges in the management of visceral leishmaniasis. Sundar S; Kumar A Indian Pediatr; 2005 Jun; 42(6):523-6. PubMed ID: 15995268 [No Abstract] [Full Text] [Related]
8. [Treatment of leishmaniasis (author's transl)]. Barabe P Med Trop (Mars); 1981; 41(6):599-605. PubMed ID: 7339417 [TBL] [Abstract][Full Text] [Related]
9. Visceral leishmaniasis in an English girl. Chapman RL Proc R Soc Med; 1973 Nov; 66(11):1110. PubMed ID: 4777030 [No Abstract] [Full Text] [Related]
10. Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases. Patel TA; Lockwood DN Trop Med Int Health; 2009 Sep; 14(9):1064-70. PubMed ID: 19552658 [TBL] [Abstract][Full Text] [Related]
11. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration. Manfredi R; Marinacci G; Calza L; Passarini B Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464 [No Abstract] [Full Text] [Related]
12. ["Imported" visceral leishmaniasis (case report and several aspects of the problem)]. Demidova AE; Andreeva NE; Margulis MI; Ul'ianova VI Ter Arkh; 1976; 48(12):52-7. PubMed ID: 1013895 [No Abstract] [Full Text] [Related]
13. Secondary prophylaxis for visceral leishmaniasis in HIV-infected individuals. Pérez-Molina JA; López-Vélez ; Guerrero A Am J Med; 1997 Jan; 102(1):132. PubMed ID: 9209216 [No Abstract] [Full Text] [Related]
14. Modifications of leucocyte function in visceral leishmaniasis. Lazzarin A; Esposito R; Almaviva M Boll Ist Sieroter Milan; 1981 Jul; 60(3):222-4. PubMed ID: 7326097 [No Abstract] [Full Text] [Related]
15. Treatment of visceral leishmaniasis in a patient with AIDS with antimony and gamma-interferon: remission and prevention of relapse by maintenance therapy with weekly pentamidine. Lustig V; Kager PA; Meenhorst PL Neth J Med; 1995 Aug; 47(2):66-9. PubMed ID: 7566284 [TBL] [Abstract][Full Text] [Related]
16. [Visceral leishmaniasis in 2 siblings and their father]. Haarscher A; Gardéa A; de Benoist B; Kien T; Rohmer A Pediatrie; 1978 Dec; 33(8):801-10. PubMed ID: 724372 [No Abstract] [Full Text] [Related]
17. Chemotherapy of cutaneous and visceral leishmaniasis in laboratory animals. Beveridge E; Neal RA Dermatol Int; 1967; 6(3):163-4. PubMed ID: 5590119 [No Abstract] [Full Text] [Related]
18. [Kala-azar in infants]. Fournier A; Henninot E; Ducoulombier H; Cousin J; Duhamel M J Sci Med Lille; 1971 Mar; 89(3):115-20. PubMed ID: 5126293 [No Abstract] [Full Text] [Related]
19. [A case of visceral leishmaniasis]. Nemery A; Duvivier A; Lefèbvre P Rev Med Liege; 1984 Mar; 39(6):238-42. PubMed ID: 6718878 [No Abstract] [Full Text] [Related]
20. Ketoconazole in the treatment of antimony- and pentamidine-resistant kala-azar. Wali JP; Aggarwal P; Gupta U; Saluja S; Singh S J Infect Dis; 1992 Jul; 166(1):215-6. PubMed ID: 1607703 [No Abstract] [Full Text] [Related] [Next] [New Search]